Abstract
The main objective of our studies has been to optimize the effects of monoclonal antibodies (MAbs) and other immunosuppressive reagents to enhance organ graft survival. One such agent is OKT3, a MAb that is directed against the CD3 component of the human T-cell receptor (TCR) complex. Treatment of a rejection episode with OKT3 results in a rapid and efficient clearing of circulating T cells and reversal of most rejection episodes. Its wider use in transplantation and in the treatment of immune-mediated disease is limited by adverse reactions that follow the initial dose, the production of neutralizing Abs, and the transient nature of the immunosuppression. We have engineered CDR-grafted “humanized” anti-CD3 MAbs that lack Fc-receptor binding activity through mutagenesis of amino acids in the Fc portion of the MAb. This results in an immunosuppressive anti-CD3 MAb that is less antigenic and one that does not induce the first-dose side effects. In addition, we have pursued a goal of developing a therapy that will induce donor-specific tolerance while maintaining overall recipient immune competency. Because antigen-specific T-cell activation depends not only on TCR-ligand interaction, but also on additional costimulatory signals mediated by accessory molecules such as CD28, blocking the binding of CD28 on T cells to its ligand B7, during TCR engagement, might modulate transplantation responses. Using a soluble fusion protein of human CTLA4, CTLA4-Ig, that binds B7 with high affinity, inhibition of human pancreatic islet rejection that occurs, at least in part, by affecting T-cell recognition of human B7+ antigen-presenting cells has been demonstrated. In addition, CTLA4-Ig induces long-term, donor-specific unresponsiveness.
Similar content being viewed by others
References
Salmeron A, Sanchez-Madrid F, Ursa MA, Fresno M, Alarcon B: A conformational epitope expressed upon association of CD3-ε with either CD3-δ or CD3-γ is the main target for recognition by anti-CD3 monoclonal antibodies. J Immunol 147:3047–3052, 1991
Van Wauwe JP, De Mey JR, Chatenoud L, Baudrihaye MF, Kreis H, Goldstein G, Schindler J, Bach J-F: Humanin vivo antigenic modulation induced by the anti-T-cell OKT3 monoclonal antibody. Eur J Immunol 12:979, 1982
Cosimi AB, Burton RC, Colvin B, Goldstein G, Delmonico F, LaQuaglia MP, Tolkoff-Rubin N, Rubin RH, Herrin JT, Russell RS: Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 32:535, 1981
Debure A, Chkoff N, Chatenoud L, LaCombe M, Campos H, Noel LH, Goldstein G, Bach J-F, Kreis H: One month prophylactic use of OKT3 in cadaver kidney transplant recipients. Transplantation 45:546, 1988
Ortho Multicenter Transplant Study Group: A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313:337, 1985
Chatenoud L: Monoclonal antibodies. Curr Opin Immunol 2:246, 1989
Abramowicz D, Goldman M, De Pauw L, Vanherweghem JL, Kinnaert P, Vereerstraeten P: The long-term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation. A single-center prospective randomized study. Transplantation 54:433, 1992
Leo O, Foo M, Sachs DH, Samelson LE, Bluestone J: Identification of a monoclonal antibody specific for murine T3 polypeptide. Proc Natl Acad Sci USA 84:1374, 1987
Hirsch R, Gress RE, Pluznik DH, Eckhaus M, Bluestone JA: Effects ofin vivo administration of anti-CD3 monoclonal antibody on T-cell function in mice: II.In vivo activation of T cells. J Immunol 142:737, 1989
Thistlethwaite JR, Stuart JK, Mayes JT, Gaber AO, Woodle S, Buckingham MR, Stuart FP: Monitoring and complications of OKT3 therapy. Am J Kidney Dis 11:112, 1988
Toussaint C, De Pauw L, Vereerstraeten P, Kinnaert P, Abramowicz D, Goldman M: Possible nephrotoxicity of the prophylactic use of OKT3 monoclonal antibody after cadaveric renal transplantation. Transplantation 48:524, 1989
Chatenoud L, Ferran C, Reuter A, Kreis H, Bach JF: Clinical use of OKT3: The role of cytokine release and xenosensitization. J Autoimmun 1:631, 1988
Abramowicz D, Schandene L, Goldman M, Crusiaux A, Vereerstraeten P, De Pauw L, Wybran J, Kinnaert P, Dupont E, Toussaint C: Release of tumor necrosis factor-α and interferon-γ in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 47:606, 1989
Chatenoud L, Ferran C, Reuter A, Legendre C, Gevaert Y, Kreis H, Franchimont P, Bach J-F: Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-γ. N Engl J Med 320:1420, 1989
Debets JM, Van de Winkel JG, Cueppens IE, Dieteren M, Buurman WA: Cross-linking of both FcγRI and FcγRII induces secretion of tumor necrosis factor by human monocytes, requiring high affinity Fc-FcγR interactions: functional activation of FcγRII by treatment with proteases or neuraminidase. J Immunol 144:1304, 1990
Krutmann J, Kirnbauer R, Kock A, Schwarz T, Schopf E, May T, Sehgal PB, Luger TA: Cross-linking Fc receptors on monocytes triggers IL-6 production. Role in anti-CD3 induced T-cell activation. J Immunol 145:1337, 1990
Hirsch R, Chatenoud L, Gress RE, Bach JF, Sachs DH, Bluestone JA: Suppression of the humoral response to anti-CD3 mAb by pretreatment with anti-CD4 mAb. Transplant Proc 21:1015, 1989
Hirsch R, Eckhaus M, Auchincloss HJ, Sachs DH, Bluestone JA: Effects ofin vivo administration of anti-CD3 monoclonal antibody on T-cell function in mice. I. Immuno-suppression of transplantation responses. J Immunol 140:3766, 1988
Ferran C, Sheehan K, Dy M, Schreiber R, Merite S, Landais P, Noel LH, Grau G, Bluestone J, Bach J-F, Chatenoud L: Cytokine-related syndrome following injection of anti-CD3 monoclonal Ab: Further evidence for transientin vivo T-cell activation. Eur J Immunol 20:509, 1990
Alegre M, Vandenabeele P, Flamand V, Moser M, Leo O, Abramowicz D, Urbain J, Fiers W, Goldman M: Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: Role of tumor necrosis factor. Eur J Immunol 20:707, 1990
Alegre M, Depierreux M, Florquin S, Abramowicz D, Najdovski T, Flamand V, Leo O, Deschodt-Lanckman M, Goldman M: Acute toxicity of anti-CD3 monoclonal antibody in mice: A model for OKT3 first dose reactions. Transplant Proc 22:1920, 1990
Flamand V, Abramowicz D, Goldman M, Biernaux C, Huez G, Urbain J, Moser M, Leo O: Anti-CD3 antibodies induce T cells from unprimed animals to secrete IL-4 bothin vitro andin vivo. J Immunol 144:2875, 1990
Gresser I, Woodrow D, Moss J, Maury C, Tavernier J, Fiers W: Toxic effects of recombinant tumor necrosis factor in sucking mice. Am J Pathol 128:13, 1987
Alegre ML, Gastaldello K, Abramowicz D, Kinnaert P, Vereerstraeten P, De Pauw L, Vandenabeele P, Moser M, Leo O, Goldman M: Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome. Transplantation 52:674, 1991
Alegre ML, Vandenabeele P, Depierreux M, Florquin S, Deschodt-Lanckman M, Flamand V, Moser M, Leo O, Urbain J, Fiers W, Goldman M: Cytokine release syndrome induced by the 145-2C11 anti-CD3 monoclonal antibody in mice: Prevention by high doses of methylprednisolone. J Immunol 146:1184, 1991
Ferran C, Dy M, Merite S, Sheehan K, Schreiber R, Leboulenger F, Landais P, Bluestone J, Bach JF, Chatenoud L: Corticosteroids reduce morbidity and cytokine release in anti-CD3 MoAb-treated mice. Transplantation 50:642, 1990
Goldman M, Abramowicz D, De Pauw L, Alegre M-L, Widera I, Vereerstraeten P, Kinnaert P: OKT3-induced cytokine release attenuation by high dose methylprednisolone. Lancet 2:802, 1989
Chatenoud L, Ferran C, Legendre C, Thouard I, Merite S, Reuter A, Gevaert Y, Kreis H, Franchimont P, Bach J-F:In vivo cell activation following OKT3 administration: Systemic release and modulation by corticosteroids. Transplantation 49:697, 1990
Goossens JG: OKT3: A monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. J Immunol 124:2708, 1980
van Lier RA, Brouwer M, Rebel VI, van Noesel CJ, Aarden LA: Immobilized anti-CD3 monoclonal antibodies induce accessory cell-independent lymphokine production, proliferation and helper activity in human T lymphocytes. Immunology 68:45, 1989
Parleviet KJ, Jonker M, ten Berge RJ, van Lier RA, Wilmink JM, Strengers PF, Aarden LA, Schellekens PT: Anti-CD3 murine monoclonal isotype switch variants tested for toxicity and immunologic monitoring in four chimpanzee. Transplantation 50:889, 1990
Hirsch R, Bluestone JA, DeNenno L, Gress RE: Anti-CD3 F(ab')2 fragments are immunosuppressivein vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation 49:1117, 1990
Hirsch R, Bluestone JA, Bare CV, Gress RE: Advantages of F(ab')2 fragments of anti-CD3 monoclonal antibody as compared to whole antibody as immunosuppressive agents in mice. Transplant Proc 23:270, 1991
Hirsch R, Archibald J, Gress RE: Differential T-cell hyporesponsiveness induced byin vivo administration of intact or F(ab′)2 fragments of anti-CD3 monoclonal antibody: F(ab′)2 fragments induce a selective T helper dysfunction. J Immunol 147:2088, 1991
Woodle SE, Thistlethwaite JR, Jolliffe LK, Zivin RA, Collins A, Adair JR, Bodmer M, Athwal D, Alegre ML, Bluestone JA: Humanized OKT3 antibodies: Successful transfer of immune modulating properties and idiotype expression. J Immunol 148:2756, 1991
Alegre ML, Collins AM, Pulito VL, Brosius RA, Olson WC, Zivin RA, Knowles R, Thistlethwaite JR, Jolliffe LK, Bluestone JA: Effect of a single amino acid mutation on the activating and immunosuppressive properties of a “humanized” OKT3 monoclonal antibody. J Immunol 148:3461, 1992
Krowka JF, Sarin S, Namikawa R, McCune JM, Kaneshima H: Human T cells in the SCID-hu mouse are phenotypically normal and functionally competent. J Immunol 146:3751, 1991
Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP: CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356:607, 1992
Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA: CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174:561, 1991
Lenschow DJ, Zeng Y, Thistlethwaite JR, Montag A, Brady W, Gibson M, Linsley PS, Bluestone JA: Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4-Ig. Science 257:789, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Alegre, ML., Lenschow, D.J. & Bluestone, J.A. Immunomodulation of transplant rejection using monoclonal antibodies and soluble receptors. Digest Dis Sci 40, 58–64 (1995). https://doi.org/10.1007/BF02063942
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02063942